b2/20220119085815okyddzEyf6.png){kind=small}
Edesa Biotech
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Spy Ct, Markham, Ontario, L3R 5H6, C...Phone Number
(289) 800-9600Website
www.edesabiotech.comRevenue
<$5 MillionStock Symbol
EDSAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Edesa Biotech
Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing treatments that address significant unmet medical needs. Edesa's lead product candidate, EB01, is a non-steroidal anti-inflammatory molecule for the treatment of chronic allergic contact dermatitis. Edesa Biotech is based in Markham, Canada, and was founded in 2007.Explore more
Edesa Biotech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Edesa Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Edesa Biotech is spiking on competitors!
Funding: Get notified immidiatlly once Edesa Biotech has new funding data
Congratulate Masked Content for being promoted to Masked Content at Edesa Biotech
Product Launch: Get notified when Edesa Biotech launches new products
Click to see if Edesa Biotech had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Edesa Biotech recently announced quarterly report
Edesa Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Edesa Biotech has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Edesa Biotech
Find more new buyers
Compare Similar Companies to Edesa Biotech
Compare insights from companies similar to Edesa Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Edesa Biotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Edesa Biotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Edesa Biotech.
Edesa Biotech financials insights
Gather financial insights about Edesa Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$7M
Edesa Biotech Tech Stack
A closer look at the technologies used by Edesa Biotech
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Earnings
Asset Management
Edesa Biotech News & Media
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress.Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it will present data on paridiprubart, its first-in-class anti-TLR4 antibody, at the 63rd European Renal Association (ERA) Congress, to be held June 3 – 6, 2026, in Glasgow, Scotland. The ERA Congress is one of the world's leading nephrology meetings, convening clinicians and researcheEdesa Biotech Reports Fiscal 2nd Quarter 2026 Results
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2026 and provided an update on its business.Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment
Edesa Biotech Inc. (NASDAQ:EDSA) is one of the 10 Unstoppable Stocks That Could Double Your Money. Edesa Biotech Inc. (NASDAQ:EDSA) is one of the unstoppable stocks that could double your money. On March 26, Edesa reaffirmed that enrollment for its Phase 2 clinical study of EB06, which is a treatment for moderate-to-severe nonsegmental vitiligo, is […]
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Edesa Biotech
Sign Up For FreeTo access detailed company insights
Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing treatments that address significant unmet medical needs. Edesa's lead product candidate, EB01, is a non-steroidal anti-inflammatory molecule for the treatment of chronic allergic contact dermatitis. Edesa Biotech is based in Markham, Canada, and was founded in 2007.... Read More
